Your search for bevacizumab returned 7 results

Pembrolizumab plus chemotherapy with or without bevacizumab could be a new standard of care for first-line therapy in metastatic cervical cancer.

The checkpoint inhibitor cemiplimab improved survival in patients with recurrent/metastatic cervical carcinoma compared with single-agent chemotherapy.

There was no improvement in overall survival with bevacizumab.

The addition of sorafenib to chemotherapy improved progression-free survival in patients with advanced breast cancer who had been previously treated with bevacizumab, according to results of a study in the TIES (Trials to Investigate Efficacy of Sorafenib) program presented at the American Society of Clinical Oncology’s 2011 Annual Meeting.

Axitinib demonstrated a significantly longer progression-free survival and higher objective response compared with sorafenib as second-line therapy for metastatic renal cell carcinoma, investigators Brian I. Rini, MD, of the Cleveland Clinic, and colleagues reported at the American Society of Clinical Oncology’s 2011 Annual Meeting.

Bevacizumab + carboplatin/gemcitabine followed by bevacizumab until disease progression provided a clinically meaningful benefit in women with platinum-sensitive recurrent ovarian cancer, representing the first Phase 3 trial of an antiangiogenic agent to demonstrate such a benefit, investigators reported during the American Society of Clinical Oncology’s 2011 Annual Meeting.

The addition of bevacizumab to carboplatin and paclitaxel chemotherapy for the first-line treatment of women with ovarian cancer may offer benefit compared with standard chemotherapy alone, particularly for patients with more aggressive disease, investigators noted in a presentation during the American Society of Clinical Oncology’s 2011 Annual Meeting.